The Suprachoroidal Space: Exploring a New Age in the Treatment of Uveitic Macular Edema (CME Symposium)

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Describe the role of the suprachoroidal space as a delivery target in the treatment of retinal diseases
  • Discuss the clinically relevant data of triamcinolone acetonide for the treatment of uveitic macular edema
  • Apply the appropriate injection technique to deliver triamcinolone acetonide into the suprachoroidal space for the treatment uveitic macular edema
  • Use evidence-based approaches for local treatment of macular edema associated with uveitis
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
Course expires: 


Quan Dong Nguyen, MD, MSc (Chair)
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, California

Peter K. Kaiser, MD
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Michael Singer, MD
Clinical Professor of Ophthalmology
University of Texas Health Science Center
Director of Clinical Research
Medical Center Ophthalmology Associates
San Antonio, Texas

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.


Peter K. Kaiser, MD, is a consultant for Aerie Pharmaceuticals, Inc, AffaMed Therapeutics, AGTS, Allegro Ophthalmics, LLC, Allergan, Allgenesis Biotherapeutics Inc, Alnylam Pharmaceuticals, Inc, Alzheon, Inc, Annexon, Inc, AsclepiX Therapeutics, Aviceda Therapeutics, Bayer Corporation, Bausch & Lomb Incorporated, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim International GmbH, Carl Zeiss Meditec, Inc, Chengdu Kanghong Pharmaceutical Group Co Ltd, Clearside Biomedical, Inc, Coherus Biosciences, Complement Therapeutics, DelSiTech Ltd, Dompé US, Inc, DTx Pharma, Duet BioTherapeutics, Eyevensys, Galecto, Inc, Galimedix Therapeutics, Inc, Glaukos Corporation, Innovent Biologics, Inc, iRenix Medical, Inc, Iveric Bio, Inc, jCyte, Kanaph Therapeutics, Kera Therapeutics, Inc, Kodiak Sciences Inc, Kriya Therapeutics, LensGen, Nanoscope Therapeutics, Inc, Novartis Pharmaceuticals Corporation, Ocugenix, Ocular Therapeutics, Oculis, Ocuphire Pharma, OcuTerra Therapeutics, Omeros Corporation, Oxurion NV, Palatin, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Resonance Medicine Inc, Retina AI Inc, Retinal Sciences, Roivant Sciences Ltd, Samsung Bioepis, SGN Nanopharma Inc, Stealth BioTherapeutics Inc, Stuart Therapeutics, Sustained Nano Systems, LLC, Takeda Pharmaceuticals USA, Inc, Thea Pharmaceuticals Limited, Unity Biotechnology, and 20/20 Onsite.

Quan Dong Nguyen, MD, MSc, is an advisory board member of Bausch & Lomb Incorporated, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc.

Michael Singer, MD, is a consultant for Allergan, EyePoint Pharmaceuticals, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc; and is on the speakers bureau for Allergan, Apellis Pharmaceuticals, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.

©2022 MedEdicus LLC. 280.1

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation


Please login or register to take this course.

Click Take course to proceed to the evaluation and to obtain your certificate.